Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials

Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. In Japan, the proportion of new patients requiring dialysis due to DKD has remained unchanged over the past five years. Early diagnosis and treatment are extremely important for...

Full description

Bibliographic Details
Main Authors:	Tomohito Gohda, Maki Murakoshi
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	International Journal of Molecular Sciences
Subjects:	chronic kidney disease diabetic kidney disease sodium-glucose cotransporter-2 inhibitor tumor necrosis factor receptors
Online Access:	https://www.mdpi.com/1422-0067/23/22/13749

Similar Items

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
by: Glenn M. Chertow, et al.
Published: (2023-05-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease
by: Tomohito Gohda, et al.
Published: (2020-03-01)

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
by: Akinobu Nakamura, et al.
Published: (2020-01-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
by: Elkeraie AF, et al.
Published: (2024-01-01)

Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice
by: Saki Ichikawa, et al.
Published: (2020-06-01)

Potential of Modulating Aldosterone Signaling and Mineralocorticoid Receptor with microRNAs to Attenuate Diabetic Kidney Disease
by: Shinji Hagiwara, et al.
Published: (2024-01-01)

Initial dip predicts renal protective effects after the administration of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and chronic kidney disease with normoalbuminuria
by: Kiyohiko Takahashi, et al.
Published: (2020-12-01)

Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
by: Emma S. Speedtsberg, et al.
Published: (2023-12-01)

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
by: Takeo Koshida, et al.
Published: (2023-07-01)

Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
by: Hidekatsu Yanai, et al.
Published: (2023-06-01)

Results of the DAPA-CKD trial and their impact on clinical practice
by: O.V. Bilchenko
Published: (2023-06-01)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
by: Cheng-Yang Hsieh, et al.
Published: (2022-12-01)

Atherosclerosis Specific Features in Chronic Kidney Disease (CKD)
by: Anastasia V. Poznyak, et al.
Published: (2022-08-01)

Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan
by: Kazuo Kobayashi, et al.
Published: (2021-08-01)

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
by: Jinfang Song, et al.
Published: (2023-09-01)

Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes
by: Hideaki Miyoshi, et al.
Published: (2019-11-01)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
by: Hirai K, et al.
Published: (2020-01-01)

Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
by: Irene Capelli, et al.
Published: (2023-04-01)

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
by: Colbert GB, et al.
Published: (2023-02-01)

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
by: Reza Mohebi, et al.
Published: (2023-07-01)

Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension
by: Nagata D, et al.
Published: (2020-07-01)

Copeptin, Natriuretic Peptides, and Cardiovascular Outcomes in Patients With CKD: The German Chronic Kidney Disease (GCKD) Study
by: Markus P. Schneider, et al.
Published: (2023-11-01)

Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study
by: Shengnan Chen, et al.
Published: (2022-12-01)

Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease
by: Yang Yang, et al.
Published: (2022-05-01)

Recent advances in the treatment of patients with obesity and chronic kidney disease
by: Roshaida Abdul Wahab, et al.
Published: (2023-12-01)

Pediatric Acute Kidney Injury to the Subsequent CKD Transition
by: Fang Wang, et al.
Published: (2020-11-01)

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context
by: Brendon L. Neuen, et al.
Published: (2024-02-01)

Variability in CKD Biomarker Studies: Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Kidney Disease Progression in the Chronic Kidney Disease in Children (CKiD) StudyPlain-Language Summary
by: Alison G. Abraham, et al.
Published: (2021-09-01)

Risk score for first-screening of prevalent undiagnosed chronic kidney disease in Peru: the CRONICAS-CKD risk score
by: Rodrigo M. Carrillo-Larco, et al.
Published: (2017-11-01)

From Acute to Chronic: Unraveling the Pathophysiological Mechanisms of the Progression from Acute Kidney Injury to Acute Kidney Disease to Chronic Kidney Disease
by: Tzu-Hsuan Yeh, et al.
Published: (2024-02-01)

Mediterranean Diet and Chronic Kidney Disease (CKD): A Practical Approach
by: Almudena Pérez-Torres, et al.
Published: (2022-12-01)

Obesity and Other Nutrition Related Abnormalities in Pre-Dialysis Chronic Kidney Disease (CKD) Participants
by: Zarina Ebrahim, et al.
Published: (2020-11-01)

Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study
by: Takeshi Horii, et al.
Published: (2022-01-01)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
by: Jing‐Wei Li, et al.
Published: (2022-08-01)

Development and validation of Chronic Kidney Disease Knowledge, Attitude, and Practices (CKD-KAP) questionnaire
by: Muhammad Haseeb Tariq, et al.
Published: (2022-10-01)

Association Between Serum High‐Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW‐CKD
by: Ki Heon Nam, et al.
Published: (2019-03-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Editorial: Nutritional Aspects of Kidney Disease
by: Alice Sabatino, et al.
Published: (2021-11-01)